Copyright Reports & Markets. All rights reserved.

Global Low Molecular Weight Heparin Market Research Report 2012-2024

Request for Sample of this report
Buy now

Table of Contents

    1 Market Overview

    • 1.1 Objectives of Research
      • 1.1.1 Definition
      • 1.1.2 Specifications
    • 1.2 Market Segment
      • 1.2.1 by Type
        • 1.2.1.1 Enoxaparin
        • 1.2.1.2 Dalteparin
        • 1.2.1.3 Tinzaparin
        • 1.2.1.4 Fraxiparine
      • 1.2.2 by Application
        • 1.2.2.1 Treatment of Venous Thromboembolism
        • 1.2.2.2 Complications of Pregnancy
        • 1.2.2.3 Cardioversion of Atrial Fibrillation/Flutter
        • 1.2.2.4 Others
      • 1.2.3 by Regions

    2 Industry Chain

    • 2.1 Industry Chain Structure
    • 2.2 Upstream
    • 2.3 Market
      • 2.3.1 SWOT
      • 2.3.2 Dynamics

    3 Environmental Analysis

    • 3.1 Policy
    • 3.2 Economic
    • 3.3 Technology
    • 3.4 Market Entry

    4 Market Segmentation by Type

    • 4.1 Market Size
      • 4.1.1 Enoxaparin Market, 2013-2018
      • 4.1.2 Dalteparin Market, 2013-2018
      • 4.1.3 Tinzaparin Market, 2013-2018
      • 4.1.4 Fraxiparine Market, 2013-2018
    • 4.2 Market Forecast
      • 4.2.1 Enoxaparin Market Forecast, 2019-2024
      • 4.2.2 Dalteparin Market Forecast, 2019-2024
      • 4.2.3 Tinzaparin Market Forecast, 2019-2024
      • 4.2.4 Fraxiparine Market Forecast, 2019-2024

    5 Market Segmentation by Application

    • 5.1 Market Size
      • 5.1.1 Treatment of Venous Thromboembolism Market, 2013-2018
      • 5.1.2 Complications of Pregnancy Market, 2013-2018
      • 5.1.3 Cardioversion of Atrial Fibrillation/Flutter Market, 2013-2018
      • 5.1.4 Others Market, 2013-2018
    • 5.2 Market Forecast
      • 5.2.1 Treatment of Venous Thromboembolism Market Forecast, 2019-2024
      • 5.2.2 Complications of Pregnancy Market Forecast, 2019-2024
      • 5.2.3 Cardioversion of Atrial Fibrillation/Flutter Market Forecast, 2019-2024
      • 5.2.4 Others Market Forecast, 2019-2024

    6 Market Segmentation by Region

    • 6.1 Market Size
      • 6.1.1 Asia-Pacific
        • 6.1.1.1 Asia-Pacific Market, 2012-2018
        • 6.1.1.2 Asia-Pacific Market by Type
        • 6.1.1.3 Asia-Pacific Market by Application
      • 6.1.2 North America
        • 6.1.2.1 North America Market, 2012-2018
        • 6.1.2.2 North America Market by Type
        • 6.1.2.3 North America Market by Application
      • 6.1.3 Europe
        • 6.1.3.1 Europe Market, 2012-2018
        • 6.1.3.2 Europe Market by Type
        • 6.1.3.3 Europe Market by Application
      • 6.1.4 South America
        • 6.1.4.1 South America Market, 2012-2018
        • 6.1.4.2 South America Market by Type
        • 6.1.4.3 South America Market by Application
      • 6.1.5 Middle East & Africa
        • 6.1.5.1 Middle East & Africa Market, 2012-2018
        • 6.1.5.2 Middle East & Africa Market by Type
        • 6.1.5.3 Middle East & Africa Market by Application
    • 6.2 Market Forecast
      • 6.2.1 Asia-Pacific Market Forecast, 2019-2024
      • 6.2.2 North America Market Forecast, 2019-2024
      • 6.2.3 Europe Market Forecast, 2019-2024
      • 6.2.4 South America Market Forecast, 2019-2024
      • 6.2.5 Middle East & Africa Market Forecast, 2019-2024

    7 Market Competitive

    • 7.1 Global Market by Vendors
    • 7.2 Market Concentration
    • 7.3 Price & Factors
    • 7.4 Marketing Channel

    8 Major Vendors

    • 8.1 Aspen
    • 8.2 Sanofi-aventis
    • 8.3 Pfizer
    • 8.4 Opocrin
    • 8.5 CSBIO
    • 8.6 Dongying Tiandong Pharmaceutical
    • 8.7 Changzhou Qianhong Bio-pharma
    • 8.8 Techdow
    • 8.9 Yantai Dongcheng Pharmaceutical Group

    9 Conclusion

    Summary
    Low Molecular Weight Heparin (LMWHs) is derived from UFH (Unfractionated heparin) by such processes as chemical degradation, enzymatic depolymerisation and gamma-radiation cleavage. Natural heparin consists of molecular chains of varying lengths, or molecular weights. Chains of varying molecular weights, from 5000 to over 40,000 Daltons, make up polydisperse pharmaceutical-grade heparin. LMWHs, in contrast, consist of only short chains of polysaccharide. LMWHs are defined as heparin salts having an average molecular weight of less than 8000 Da and for which at least 60% of all chains have a molecular weight less than 8000 Da.
    The global Low Molecular Weight Heparin market will reach xxx Million USD in 2019 with CAGR xx% 2019-2024. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to describe the content about the factors influencing market dynamics, policy, economic, technology and market entry etc.
    Based on products type, the report describes major products type share of regional market. Products mentioned as follows:
    Enoxaparin
    Dalteparin
    Tinzaparin
    Fraxiparine
    Leading vendors in the market are included based on profile, business performance etc. Vendors mentioned as follows:
    Aspen
    Sanofi-aventis
    Pfizer
    Opocrin
    CSBIO
    Dongying Tiandong Pharmaceutical
    Changzhou Qianhong Bio-pharma
    Techdow
    Yantai Dongcheng Pharmaceutical Group
    Based on Application, the report describes major application share of regional market. Application mentioned as follows:
    Treatment of Venous Thromboembolism
    Complications of Pregnancy
    Cardioversion of Atrial Fibrillation/Flutter
    Others
    Based on region, the report describes major regions market by products and application. Regions mentioned as follows:
    Asia-Pacific
    North America
    Europe
    South America
    Middle East & Africa

    Buy now